Trevi Therapeutics: Analysts See Great Opportunities for Haduvio After GSK Setback

Clear Street increases the target price for Trevi Therapeutics to $40 after rival GSK halts the development of its drug Camlipixant for refractory chronic cough. With the GSK product no longer in play, the market potential for Trevi's drug candidate Haduvio increases; furthermore, the assumed annual price of therapy has been raised by experts to $100,000. A recent capital measure strengthens the company's balance sheet and secures liquidity until 2030, ensuring the financing of ongoing phase-3 studies. A competitor withdraws The market for...